Japan approves Covaxin booster dose for travellers: Bharat Biotech – ET HealthWorld

Hyderabad-based Bharat Biotech on Friday announced that Japan has approved the Covaxin booster dose for travellers. “We are proud to announce, that Japan has approved Covaxin booster dose for travellers. Another global recognition of the effectiveness of our universal Covid vaccine,” Bharat Biotech tweeted. Quarantine Station of Japan’s Ministry of Health, Labour and Welfare issued an advisory for the Quarantine period after entering Japan. In an official statement, the ministry said, “Travelers who are entering or returning to Japan from countries/regions categorized as “RED” in border control measures(28) and who…

Read More

Bharat Biotech Expects To Get A Nod For Its Intranasal COVID-19 Vaccine By August

Bharat Biotech, which is working on an intranasal COVID-19 vaccine candidate is hopeful of getting regulatory licenses this month, if all goes well, Chairman and Managing Director of the company, Krishna Ella said. He also has said BBIL (Bharat Biotech International Limited), which has a vaccine manufacturing plant in Ankleshwar in Gujarat is one of the two plants in the world capable of producing vaccine for monkeypox disease. The other one is in Bavarian Nordic, Germany. “We will be applying for licenses and (they) should come. If everything goes well, we know…

Read More

Bharat Biotech expects regulator’s nod for intranasal COVID-19 vaccine in Aug – ET HealthWorld

Hyderabad: Bharat Biotech, which is working on an intranasal COVID-19 vaccine candidate is hopeful of getting regulatory licenses this month, if all goes well, Chairman and Managing Director of BBIL, Krishna Ella said. He also has said BBIL (Bharat Biotech International Limited), which has a vaccine manufacturing plant in Ankleshwar in Gujarat is one of the two plants in the world to manufacture vaccine for monkeypox. The other one is in Bavarian Nordic, Germany. “We will be applying for licenses and (they) should come. If everything goes well, we know…

Read More

CEPI funds consortium of ExcellGene, Bharat Biotech, University of Sydney to develop variant-proof COVID-19 vaccine – ET HealthWorld

Hyderabad: ExcellGene SA announced its role in the recently approved consortium funding through the Coalition for Epidemic Preparedness Innovations (CEPI). The consortium partnership strives to advance a new vaccine concept that confers highly cross-reactive protection against numerous SARS-CoV-2 variants of concern (VoCs) as well as other Betacoronaviruses. ExcellGene will produce complex chimeric Spike antigens using its engineered CHOExpress-cell based technology. The Swiss company will use insights from several scientific and technical disciplines along with artificial intelligence (AI) to identify the most promising antigenic structure. Together with Bharat Biotech, and Prof…

Read More

Covaxin’s third dose demonstrates persistence of immunity against emerging COVID variants – ET HealthWorld

New Delhi: Hyderabad-based vaccine developer Bharat Biotech on Wednesday announced the administration of third dose of its COVID-19 vaccine BBV152 also known as Covaxin, after six months of two-dose vaccination, dramatically increased neutralizing antibody responses against both homologous and heterologous strains and showed increased memory B cell response. The study was conducted on 184 subjects, who were randomized 1:1 and received either a booster dose of BBV152 or a placebo, 6 months after the primary series of 2 doses. Covaxin induced robust T cell responses and persisted till 6 months,…

Read More

Bharat Biotech’s Covid-19 nasal vaccine phase III trials completed – ET HealthWorld

Hyderabad: Dr Krishna Ella, Chairman and Managing Director of Bharat Biotech on Saturday (local time) said that the clinical phase III trials of the Covid-19 nasal vaccine have been completed and the company will submit its data with Drugs Controller General of India (DCGI) next month. In an exclusive interview with ANI, Dr Ella said, “We just completed a clinical trial, a data analysis is going on. Next month, we will submit the data to the regulatory agency. If everything is okay, then we will get permission to launch and…

Read More

Covaxin safe and highly immunogenic in children 2-18 years : Lancet journal review – ET HealthWorld

Hyderabad : Bharat Biotech’s BBV152 (COVAXIN), its whole-virion inactivated COVID-19 vaccine candidate is proven to be safe, well-tolerated, and immunogenic in the paediatric population in phase II/III studies, showed a study published in the peer-reviewed journal The Lancet Infectious diseases. The Hyderabad based vaccine maker informed that they have a stockpile of more than 50 million doses of COVAXIN ready to be distributed as required. Bharat Biotech has established COVAXIN manufacturing to reach an annualised capacity of 1 billion doses by the end of 2021. Sharing the details on the…

Read More

Covaxin booster dose enhances vaccine effectiveness against Delta, Omicron variants, says ICMR study – ET HealthWorld

New Delhi: The administration of Covaxin as a booster dose enhances vaccine effectiveness against COVID-19’s Delta variant and gives protection against Omicron variants BA.1.1 and BA.2, a study by ICMR and Bharat Biotech has found. The protective efficacy of Bharat Biotech’s Covaxin following two and three-dose immunisations against the Delta variant and the efficacy of the Covaxin against Omicron variants were studied in a Syrian hamster model (animal model to study human-associated diseases), it said. The antibody response, clinical observations, viral load reduction and lung disease severity after virus challenge…

Read More

Germany to recognize Bharat Biotech’s COVAXIN for travel from June 1 – ET HealthWorld

New Delhi: German Ambassador to India, Walter J Lindner, on Thursday hailed the German government for recognizing the WHO-listed Bharat Biotech‘s COVID vaccine, COVAXIN, for travel to the country starting June 1. World Health Organization (WHO) in November last year issued an emergency use listing (EUL) for COVAXIN, adding to a growing portfolio of vaccines validated for the prevention of COVID-19 caused by SARS-CoV-2. Taking to Twitter, the Ambassador to Germany and Bhutan Lindner wrote, “Very happy that GER government just decided to recognize WHO-listed Covaxin for travels to GER,…

Read More

CEPI partners with Bharat Biotech Consortium to develop ‘variant-proof’ COVID-19 vaccine – ET HealthWorld

Picture used for representational purpose only Hyderabad : The Coalition for Epidemic Preparedness Innovations (CEPI) Tuesday announced the latest award under its $200m programme to advance the development of vaccines that provide broad protection against SARS-Cov-2 variants and other betacoronaviruses. CEPI will provide funding of up to US$19.3 million to support the development of a ‘variant-proof’ SARS-CoV-2 vaccine candidate to an international multidisciplinary consortium comprising Bharat Biotech International Ltd (BBIL), India, the University of Sydney, Australia and ExcellGene SA, Switzerland. CEPI’s funding will support the consortium as it seeks to…

Read More